BioAffinity Technologies received a patent allowance for its CyPath Lung test from the Japan Patent Office, causing its stock to soar.
1 report, 1 independent
Updated 00:00
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
BioAffinity Technologies received a patent allowance for its CyPath Lung test from the Japan Patent Office, causing its stock to soar.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Japan Patent Office
Japanese governmental agency
Nothing else this week.
-
Nasdaq
American fully electronic stock exchange